Biotage
Price
Price
CHART BY
Frequently asked questions
What is the Earnings Per Share (EPS) for Biotage?
What are the analyst ratings and target price for Biotage's stock?
What is Biotage's revenue over the trailing twelve months?
What is the EBITDA for Biotage?
What is the free cash flow of Biotage?
How many employees does Biotage have, and what sector and industry does it belong to?
Financials
- EPS (TTM)
- 0.323
- Revenue (TTM)
- $197.91M
- EBITDA (TTM)
- $47.13M
- Free Cashflow (TTM)
- $26.64M
Analyst Ratings
The price target is $14.63 and the stock is covered by 1 analysts.
Buy
0
Hold
1
Sell
0
Information
Biotage AB is a Swedish life science company specializing in advanced laboratory technologies and workflow solutions that support drug discovery, development, and analytical testing to improve human health. The company is based in Uppsala, Sweden. The company offers a comprehensive portfolio of systems, consumables, reagents, and accessories focused on chemical synthesis, purification, evaporation, and sample extraction and clean-up. Product categories include organic and peptide synthesis, biomolecule purification, flash chromatography, solid-phase and supported liquid extraction, filtration, and evaporation technologies. Biotage provides automated sample preparation workstations, advanced peptide synthesizers, specialized solid-supported reagents, chromatography resins, prepacked columns, cartridges, and plates for various purification needs. The company's solutions are used in bioanalysis, forensic toxicology, environmental testing, food safety, doping control, and biomolecule purification, and are supported by knowledge resources, customer service, application support, and software tools. The company serves customers in pharmaceutical, biotech, contract research and manufacturing, clinical, forensic, academic laboratories, and organizations focused on food safety, clean water, and environmental sustainability. and has a global presence of subsidiaries in several regions. The company was founded in 1969 by Bengt Falk, Bertil Pettersson, Björn Lennart Ekström, Carl Erik Mathias Uhlén, Mostafa Ronaghi, Neil Goldsmith, Pal Nyrén, Sheridan G. Snyder. Frederic Vanderhaegen has been the CEO of the company since 2024.
- Employees
- 673
- Industries
- Medical Specialties
- Sector
- Health Care
Identifier
- ISIN
- SE0000454746
- Primary Ticker
- BIOT